PMCCPMCCPMCC

Search tips
Search criteria 

Advanced


 
Formats
Article sections
Authors
Related links
 
AIDS Res Hum Retroviruses. 2012 January; 28(1): 49–53.
PMCID: PMC3251837
Copyright 2012, Mary Ann Liebert, Inc.
cAMP During HIV Infection: Friend or Foe?
Maria E. Moreno-Fernandez,1,* Cesar Mauricio Rueda,2,* Paula A. Velilla,2 Maria Teresa Rugeles,2 and Claire A. Chougnetcorresponding author1
1Division of Molecular Immunology, Cincinnati Children's Hospital Research Foundation, Department of Pediatrics, Immunobiology Graduate Program University of Cincinnati, College of Medicine, Cincinnati, Ohio.
2Grupo Inmunovirologia, Universidad de Antioquia, Medellin, Antioquia, Colombia.
corresponding authorCorresponding author.
Address correspondence to: Claire Chougnet, Division of Molecular Immunology, Cincinnati Children's Hospital Research Foundation, Department of Pediatrics, Immunobiology Graduate Program University of Cincinnati, College of Medicine, Cincinnati, Ohio 45229. E-mail:claire.chougnet/at/cchmc.org
*These authors contributed equally to this work.
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
Intracellular levels of cyclic adenosine 3',5'-monophosphate (cAMP) are important regulators of immune cells, partially determining the balance between activation and suppression. In this review, we discuss the mechanisms by which HIV infection increases cAMP levels in T cells, as well as the effect of cAMP on HIV-specific responses and its effect on HIV replication and infection. Results suggest that increased cAMP levels during HIV infection may have a dual and opposite roles. On the one hand, they could have a protective effect by limiting viral replication in infected cells and decreasing viral entry. On the other hand, they could have a detrimental role by reducing HIV-specific antiviral immune responses, thus reducing the clearance of the virus and contributing to T cell dysfunction. Future studies are thus needed to further define the beneficial versus detrimental roles of cAMP, as they could help establish new therapeutic targets to combat HIV replication and/or identify novel ways to boost antiviral immune responses.
Introduction
Virological and immunological factors contribute to the pathogenesis of human immunodeficiency virus type 1 (HIV-1) infection. Several studies have shown that T cells from HIV-infected patients exhibit a high cyclic adenosine 3',5'-monophosphate (cAMP) concentration. As levels of intracellular cAMP are important regulators of immune cells, partially determining the balance between activation and suppression, cAMP levels could play a critical role in HIV pathogenesis. Herein, we review what is known about the regulation, and role, of cAMP during HIV infection.
cAMP is a secondary messenger involved in multiple cellular processes. Activation of cAMP production is induced by signals given through many cellular receptors, mainly G-protein-coupled receptors, adrenergic and apurinergic receptors, as well as growth factor receptors.1 Intracellular levels of cAMP are controlled by two groups of enzymes, those that induce it, the adenyl cyclases (AC), and those that degrade it, the phosphodiesterases (PDE). Ten different isoforms of AC (AC1–AC10) and 11 isoforms of PDE (PDE1–PDE11) have been reported.2,3 T cell express different isoforms of AC (AC3, AC6, AC7, and AC94) and PDE (PDE1B, PDE3B, PDE4D, PDE8A, and PDE115,6). In general, AC are bound to the inner side of the cell membrane and, once activated, they transform ATP into cAMP. In contrast, PDE are mainly found in the cytoplasm and they hydrolyze cAMP to its inactive form, the adenosine 5′-monophosphate (AMP).7
Of particular interest is the fact that regulatory T cells (Treg) can induce cAMP in their target cells by increasing adenosine levels in the microenvironment, through conversion of ATP into adenosine, a process mediated by ectonucleotidases (CD39 and CD73) present at the surface of Treg.8 First, CD39 hydrolyzes ATP or ADP into 5-AMP, which is cleaved into adenosine by CD73.8 Pericellular adenosine signals through the purinergic receptor A2AR, thus inducing AC activation in Treg target cells.
An additional mechanism of increased intracellular cAMP involves influx of cAMP from Treg, through gap junctions (GJ). GJ are channels that allow intercellular communication between adjacent cells; they are formed by two opposing hemichannels from each cell, called connexons. This protein complex consists of six proteins called connexins (Cx).9 GJ are used for the bidirectional passage of ions, metabolites, and other molecules of less than 1 kDa.9 Resting T cells exhibit low density of Cx31.1, Cx32, Cx43, Cx45, and Cx46, which all increase after cellular activation.10 Previous studies have shown that Treg contain high levels of intracellular cAMP, which they can transfer through GJ to target cells, including T cells and dendritic cells (DC), and thus increase intracellular cAMP in these target cells.10,11
cAMP activation initiates several major downstream signaling cascades. The canonical pathway is the activation of the cAMP-dependent protein kinase-A (PKA). More recently, cAMP was also shown to interact with the Exchange Protein Activated by cAMP (EPAC). A third major target is the Cyclic-Nucleotide Gated Ion Channel (CNG). Together or separately, these pathways regulate the transcriptional activity of many genes involved in cell cycle, cell survival, and cytokine secretion.12 In addition to these two main pathways, cAMP directly regulates Ca2+ levels by opening ion channels. This controls T cell proliferation and cytokine production.12
PKA acts on multiple signaling molecules inside the cells, thus inhibiting the transcription of many genes. It negatively regulates the transcription factor CREB, blocking the formation of the complex with the coactivator CBP, preventing the binding to the cAMP response elements (CRE).13 These CRE binding elements are found in the promoter of many genes coding for the T cell receptor, CD3, and other molecules involved in T cell activation.14 PKA also regulates the activity of NFAT, by blocking the interaction and the formation of protein complexes, and it blocks the formation of NF-κB and CBP/p300 complex.15 In addition, PKA phosphorylate the proteins Raf-1, Ras, Mek, and HePTP in the MAPK pathway, as well as PLC-α1 and PLC-β in the phosphatidylinositol pathway.15,16
The EPAC pathway regulates the expression of several genes associated with cell cycle, affecting T cell proliferation, as well as the production of cytokines such as IL-2 and IL-5.17,18 Interestingly, anergic T cells express the active form of RAP-1, which is considered to function as a negative regulator of gene transcription induced by TCR engagement and IL-2.19 In contrast, EPAC signaling does not appear to affect the maturation and function of DC.20
In immune cells, the cAMP/PKA pathway directly modulates the proliferation and transcription of many cytokine genes, such as TNF-α, IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, and IL-12.15,21–23 Additionally, cAMP suppresses the proliferation of murine or human T cells stimulated with anti-CD3 antibody.17,24,25 Treatment of T cells with cholera toxin activates AC by inducing an ADP-ribosylation in the alpha subunit of the G protein, leading to increased cAMP levels and decreased proliferation and IL-2 production in response to stimulation. In addition, cholera toxin promotes the acquisition of regulatory functions,26 mediated by increased expression of the immune suppressive molecule cytotoxic T-lymphocyte antigen 4 (CTLA-4).27
cAMP signaling can also indirectly regulate T cell function as induction of cAMP in DC following engagement of prostaglandin and adenosine receptors negatively regulates NF-KB activity, decreasing the production of proinflammatory cytokines such as IL-12, TNF-α, IL-1α, and IL-6, while increasing the production of the antiinflammatory cytokine IL-10.28–34 In addition, cAMP affects the expression of costimulatory molecules by DC and thus their immunogenicity.29,33,35,36
Levels of cAMP in Treg also partially determine their suppressive activity. Antagonists of cAMP decrease Treg suppressive activity and increase antitumoral immune responses in patients with colon cancer.37 However, treatment of Treg with rolipram, a PDE inhibitor that prevents cAMP degradation, potentiates their suppression of Th2 cells in vivo, controlling tissue inflammation and allergic respiratory diseases.38 Inhibition of the cAMP pathway could thus constitute a therapeutic avenue in diseases in which an excessive immune regulation exerted by Treg plays a pathogenic role.
Previous studies have shown that in vitro HIV infection of T cell lines and primary T cells leads to enhanced intracellular cAMP levels.39,40,41 Moreover, ex vivo studies have shown that T cells from HIV-infected patients contain twice as much cAMP than those of HIV-uninfected individuals.41,42 Of note, these studies were done before it was recognized that Treg frequency increases during chronic HIV infection,43–46 so these later results may be, at least partially, due to the changes in subset composition. Productive infection was not required, as treatment of T cells by the HIV envelope glycoprotein 120 (gp120) was sufficient to augment cAMP levels and activate the cAMP/PKA signaling pathway.42,47,48 How HIV affects EPAC is not well understood. Similarly, the mechanism(s) by which gp120 increases cAMP are still unclear. One study described the binding of HIV gp120 to chemokine receptors as the driving mechanism, as engagement of CD4 by a specific antibody did not have the same effect as CXCR4 engagement by its natural ligand SDF-1.47 In contrast, another study suggests that cAMP induction by gp120 is mainly CD4 dependent, as Lck blockage abolished its induction.48
In addition to directly augmenting intracellular levels of cAMP, HIV could also increase cAMP levels by modulating the production of adenosine through the regulation of CD39 expression. CD4+ T cells from untreated HIV-infected patients exhibit an increase in ATPase activity, a result that was associated with a higher percentage of CD39+ T cells.49 Increased CD39 expression by Treg was reported in HIV-infected progressors compared with healthy controls and elite controllers.50,51 Moreover, during the acute phase of SIV infection in rhesus macaques, CD39 was highly expressed by the CD8+FOXP3+CD25+ T cells present in the gastrointestinal mucosa and lymphoid organs, which are sites of active viral replication.52 This increased CD39 expression on T cells may limit viral infection by decreasing levels of extracellular ATP. Indeed, ATP has recently been shown to facilitate viral entry, as it promotes the fusion of viral membrane and host cell membrane in a pathway involving binding of ATP to purinergic receptors.53
Several studies have shown that activation of the cAMP pathway could inhibit HIV-specific immune responses. In particular, gp120 binding to CXCR4 decreased the proliferation of CD4+ and CD8+ T cells in response to polyclonal stimuli, through PKA-dependent activation of CREB.40,47 In contrast, decreasing intracellular cAMP generation by chemical inhibition of AC restored the proliferation and cytotoxicity of T cells.40,42 Another mechanism of cAMP-mediated suppression is its effect on Treg: HIV gp120 potentiated Treg-mediated suppression by increasing CTLA-4 levels on these cells.48 Moreover, blocking CD39 activity boosted the production of cytokines by HIV-specific T cells.51 Taken together, these results may explain the relative protection against development of AIDS associated with a CD39 gene polymorphism that leads to low CD39 expression.51
All together, the studies mentioned above suggest that cAMP plays a detrimental role during HIV infection because it can suppress the antiviral immune responses. However, other data suggest that it plays a more complex role as it can also directly inhibit viral replication (Fig. 1). Increased levels of cAMP either following in vitro AC activation with synthetic compounds such as forskolin, or after blockage of cAMP degradation by rolipram, diminished viral transcription and levels of HIV-p24Gag protein in activated T cells.54,55 In addition, ATP treatment of HIV-infected immature DC induced lysosomal degradation of the virus and blocked virus transfer from DC to CD4+ T cells.56 In infected primary T cells, monocytes, and cell lines, cAMP activates the CREB protein, which competes with phosphorylated NF-κB for limiting amounts of CBP/p300, suppressing HIV-LTR transcription activity in infected cells.57–59 In naive T cells, cAMP significantly decreased nuclear import, translocation, and replication of viral DNA, compared to memory T cells, suggesting that the cAMP/PKA pathway can affect HIV infection at both pre- and postintegration steps.55
FIG. 1.
FIG. 1.
Effect of increased cAMP levels in HIV replication. The scheme illustrates the various mechanisms by which increased levels of cAMP may affect HIV replication and spread. The red circles represent the effect of increased cAMP in conventional T cells (Tcon), (more ...)
cAMP could also limit HIV infection by decreasing the expression of viral receptors on the surface of target cells. In particular, stimulation of the PGE2 receptor, which induces cAMP in monocytes and macrophages, decreases their expression of CCR5.60 Similar regulation occurs in CD4+ T cells, in which activation of the cAMP pathway following stimulation of adenosine receptors reduces the expression of the coreceptors CXCR4 and CCR5.61
Another level of control of HIV replication that involves cAMP is the one exerted by Treg. Recently, using an in vitro model of HIV infection, we showed that Treg limit HIV infection in conventional T cells using a cAMP-mediated pathway involving both transfer of cAMP through GJ and CD39 activity. This reduction of HIV infection in conventional T cells implicated the PKA pathway, because inhibition of PKA activation in target cells abolished Treg suppression of HIV infection.62 Furthermore, cAMP from Treg likely inhibits DC activation as Treg and DC form GJ.11 As the level of activation of DC is a critical factor in their transfer of virus to CD4+ T cells, increased cAMP in DC may also limit this transfer. This function of Treg has not yet been investigated, but its potential to limit early viral spread warrants further investigation. Of note, the effect of cAMP-mediated EPAC activation on HIV immune responses or HIV replication is not yet established. However, as EPAC controls the expression of many genes involved in T cell activation and cell cycle, this pathway also deserves further investigation.63
Experimental evidence suggest that cAMP has dual and opposite roles during HIV infection. On the one hand, it could have a protective effect in infected cells by limiting viral replication, decreasing viral entry, or decreasing the capacity of DC to transfer the virus. On the other hand, it could have a detrimental role by reducing HIV-specific antiviral immune responses, thus reducing the clearance of the virus and contributing to T cell anergy. The balance between these functions is not known, but one could envision a model whereby the overall effect of cAMP is dependent of the stage of the infection. During the early HIV infection when the effector immune responses are not yet established, cAMP could have a mainly beneficial role, controlling T cell and DC activation, thus decreasing viral replication and viral transfer. In contrast, during the late and chronic phase of the infection when anti-HIV effector responses have been primed, high cAMP levels could decrease their efficiency, and have an overall negative effect despite its continuous capacity to decrease viral replication. It is therefore important to design more studies to evaluate the effect of cAMP activation at different stages of HIV infection. This knowledge may make it possible to establish new therapeutic targets of antiretroviral therapy or identify potential target molecules with immunoregulatory potential, which could help restore immune dysfunction.
Acknowledgments
This work was supported by Public Health Service Grants AI068524 (to C.C.) and by Colciencias 111540820490-1 (to C.M.R.). We thank Drs. Dave Hildeman and Gene Shearer for critical review of this manuscript.
Author Disclosure Statement
No competing financial interests exist.
References
1. Watts VJ. Neve KA. Sensitization of adenylate cyclase by Galpha i/o-coupled receptors. Pharmacol Ther. 2005;106(3):405–421. [PubMed]
2. Sunahara RK. Taussig R. Isoforms of mammalian adenylyl cyclase: Multiplicities of signaling. Mol Interv. 2002;2(3):168–184. [PubMed]
3. Beavo JA. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev. 1995;75(4):725–748. [PubMed]
4. Bazhin AV. Kahnert S. Kimpfler S. Schadendorf D. Umansky V. Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. Mol Immunol. 2010;47(4):678–684. [PubMed]
5. Marson A. Kretschmer K. Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 2007;445(7130):931–935. [PMC free article] [PubMed]
6. Zheng Y. Josefowicz SZ. Kas A. Chu TT. Gavin MA. Rudensky AY. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445(7130):936–940. [PubMed]
7. Omori K. Kotera J. Overview of PDEs and their regulation. Circ Res. 2007;100(3):309–327. [PubMed]
8. Sitkovsky M. Lukashev D. Deaglio S. Dwyer K. Robson SC. Ohta A. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol. 2008;153(Suppl 1):S457–464. [PubMed]
9. Fonseca PC. Nihei OK. Savino W. Spray DC. Alves LA. Flow cytometry analysis of gap junction-mediated cell-cell communication: advantages and pitfalls. Cytometry A. 2006;69(6):487–493. [PubMed]
10. Bopp T. Becker C. Klein M, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med. 2007;204(6):1303–1310. [PMC free article] [PubMed]
11. Ring S. Karakhanova S. Johnson T. Enk AH. Mahnke K. Gap junctions between regulatory T cells and dendritic cells prevent sensitization of CD8(+) T cells. J Allergy Clin Immunol. 2010;125(1):237–246. [PubMed]
12. Gray PC. Scott JD. Catterall WA. Regulation of ion channels by cAMP-dependent protein kinase and A-kinase anchoring proteins. Curr Opin Neurobiol. 1998;8(3):330–334. [PubMed]
13. Kwok RP. Lundblad JR. Chrivia JC, et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature. 1994;370(6486):223–226. [PubMed]
14. Gupta A. Terhorst C. CD3 delta enhancer. CREB interferes with the function of a murine CD3-delta A binding factor (M delta AF) J Immunol. 1994;152(8):3895–3903. [PubMed]
15. Borger P. Postma DS. Vellenga E. Kauffman HF. Regulation of asthma-related T-cell cytokines by the cyclic AMP-dependent signalling pathway. Clin Exp Allergy. 2000;30(7):920–926. [PubMed]
16. Torgersen KM. Vang T. Abrahamsen H. Yaqub S. Tasken K. Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal. 2002;14(1):1–9. [PubMed]
17. Bryce PJ. Dascombe MJ. Hutchinson IV. Immunomodulatory effects of pharmacological elevation of cyclic AMP in T lymphocytes proceed via a protein kinase A independent mechanism. Immunopharmacology. 1999;41(2):139–146. [PubMed]
18. Staples KJ. Bergmann M. Tomita K, et al. Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol. 2001;167(4):2074–2080. [PubMed]
19. Boussiotis VA. Freeman GJ. Berezovskaya A. Barber DL. Nadler LM. Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1. Science. 1997;278(5335):124–128. [PubMed]
20. Garay J. D'Angelo JA. Park Y, et al. Crosstalk between PKA and Epac regulates the phenotypic maturation and function of human dendritic cells. J Immunol. 2010;185(6):3227–3238. [PMC free article] [PubMed]
21. Johansson CC. Bryn T. Yndestad A, et al. Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under the control of cAMP. AIDS. 2004;18(2):171–179. [PubMed]
22. Gerlo S. Verdood P. Kooijman R. Modulation of cytokine production by cyclic adenosine monophosphate analogs in human leukocytes. J Interferon Cytokine Res. 2010;30(12):883–891. [PubMed]
23. Naganuma M. Wiznerowicz EB. Lappas CM. Linden J. Worthington MT. Ernst PB. Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol. 2006;177(5):2765–2769. [PubMed]
24. Napolitani G. Acosta-Rodriguez EV. Lanzavecchia A. Sallusto F. Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells. Eur J Immunol. 2009;39(5):1301–1312. [PubMed]
25. Sakata D. Yao C. Narumiya S. Prostaglandin E2, an immunoactivator. J Pharmacol Sci. 2010;112(1):1–5. [PubMed]
26. Vendetti S. Patrizio M. Riccomi A. De Magistris MT. Human CD4+ T lymphocytes with increased intracellular cAMP levels exert regulatory functions by releasing extracellular cAMP. J Leukoc Biol. 2006;80(4):880–888. [PubMed]
27. Vendetti S. Riccomi A. Sacchi A. Gatta L. Pioli C. De Magistris MT. Cyclic adenosine 5'-monophosphate and calcium induce CD152 (CTLA-4) up-regulation in resting CD4+ T lymphocytes. J Immunol. 2002;169(11):6231–6235. [PubMed]
28. Zhou W. Hashimoto K. Goleniewska K, et al. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J Immunol. 2007;178(2):702–710. [PubMed]
29. Ben Addi A. Lefort A. Hua X, et al. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B) receptor. Eur J Immunol. 2008;38(6):1610–1620. [PubMed]
30. Nemeth ZH. Lutz CS. Csoka B, et al. Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism. J Immunol 15. 2005;175(12):8260–8270. [PMC free article] [PubMed]
31. Hasko G. Kuhel DG. Chen JF, et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 2000;14(13):2065–2074. [PubMed]
32. Hasko G. Szabo C. Nemeth ZH. Kvetan V. Pastores SM. Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol. 1996;157(10):4634–4640. [PubMed]
33. Wilson JM. Ross WG. Agbai ON, et al. The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol. 2009;182(8):4616–4623. [PMC free article] [PubMed]
34. Son Y. Ito T. Ozaki Y, et al. Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells. Immunology. 2006;119(1):36–42. [PubMed]
35. Borsellino G. Kleinewietfeld M. Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110(4):1225–1232. [PubMed]
36. Novitskiy SV. Ryzhov S. Zaynagetdinov R, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112(5):1822–1831. [PubMed]
37. Yaqub S. Tasken K. Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit Rev Oncog. 2008;14(1):57–77. [PubMed]
38. Bopp T. Dehzad N. Reuter S, et al. Inhibition of cAMP degradation improves regulatory T cell-mediated suppression. J Immunol. 2009;182(7):4017–4024. [PubMed]
39. Nokta M. Pollard R. Human immunodeficiency virus infection: Association with altered intracellular levels of cAMP and cGMP in MT-4 cells. Virology. 1991;181(1):211–217. [PubMed]
40. Hofmann B. Nishanian P. Nguyen T. Insixiengmay P. Fahey JL. Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes. Proc Natl Acad Sci USA. 1993;90(14):6676–6680. [PubMed]
41. Aandahl EM. Aukrust P. Skalhegg BS, et al. Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J. 1998;12(10):855–862. [PubMed]
42. Hofmann B. Nishanian P. Nguyen T. Liu M. Fahey JL. Restoration of T-cell function in HIV infection by reduction of intracellular cAMP levels with adenosine analogues. AIDS. 1993;7(5):659–664. [PubMed]
43. Andersson J. Boasso A. Nilsson J, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol. 2005;174(6):3143–3147. [PubMed]
44. Nilsson J. Boasso A. Velilla PA, et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood. 2006;108(12):3808–3817. [PubMed]
45. Estes JD. Li Q. Reynolds MR, et al. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis. 2006;193(5):703–712. [PubMed]
46. Epple HJ. Loddenkemper C. Kunkel D, et al. Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood. 2006;108(9):3072–3078. [PubMed]
47. Masci AM. Galgani M. Cassano S, et al. HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling. J Leukoc Biol. 2003;74(6):1117–1124. [PubMed]
48. Becker C. Taube C. Bopp T, et al. Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4+ CD25+ regulatory T cells. Blood. 2009;114(6):1263–1269. [PubMed]
49. Leal DB. Streher CA. Bertoncheli Cde M, et al. HIV infection is associated with increased NTPDase activity that correlates with CD39-positive lymphocytes. Biochim Biophys Acta. 2005;1746(2):129–134. [PubMed]
50. Schulze Zur Wiesch J. Thomssen A. Hartjen P, et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol. 2011;85(3):1287–1297. [PMC free article] [PubMed]
51. Nikolova M. Carriere M. Jenabian MA, et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog. 2011;7(7):e1002110. [PMC free article] [PubMed]
52. Nigam P. Velu V. Kannanganat S, et al. Expansion of FOXP3+ CD8 T cells with suppressive potential in colorectal mucosa following a pathogenic simian immunodeficiency virus infection correlates with diminished antiviral T cell response and viral control. J Immunol. 2010;184(4):1690–1701. [PubMed]
53. Séror C. Melki M-T. Subra F, et al. Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J Exp Med. 2011;208(9):1823–1834. [PMC free article] [PubMed]
54. Navarro J. Punzon C. Jimenez JL, et al. Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J Virol. 1998;72(6):4712–4720. [PMC free article] [PubMed]
55. Sun Y. Li L. Lau F. Beavo JA. Clark EA. Infection of CD4+ memory T cells by HIV-1 requires expression of phosphodiesterase 4. J Immunol. 2000;165(4):1755–1761. [PubMed]
56. Barat C. Gilbert C. Imbeault M. Tremblay MJ. Extracellular ATP reduces HIV-1 transfer from immature dendritic cells to CD4+ T lymphocytes. Retrovirology. 2008;5:30. [PMC free article] [PubMed]
57. Banas B. Eberle J. Schlondorff D. Luckow B. Modulation of HIV-1 enhancer activity and virus production by cAMP. FEBS Lett. 2001;509(2):207–212. [PubMed]
58. Rincon M. Tugores A. Lopez-Rivas A, et al. Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol. 1988;18(11):1791–1796. [PubMed]
59. Hayes MM. Lane BR. King SR. Markovitz DM. Coffey MJ. Prostaglandin E(2) inhibits replication of HIV-1 in macrophages through activation of protein kinase A. Cell Immunol. 2002;215(1):61–71. [PubMed]
60. Thivierge M. Le Gouill C. Tremblay MJ. Stankova J. Rola-Pleszczynski M. Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: Downregulation of CCR5 expression by cyclic adenosine monophosphate. Blood. 1998;92(1):40–45. [PubMed]
61. By Y. Durand-Gorde JM. Condo J, et al. Monoclonal antibody-assisted stimulation of adenosine A2A receptors induces simultaneous downregulation of CXCR4 and CCR5 on CD4+ T-cells. Hum Immunol. 2010;71(11):1073–1076. [PubMed]
62. Moreno-Fernandez ME. Rueda CM. Rusie LK. Chougnet CA. Regulatory T cells control HIV replication in activated T cells through a cAMP-dependent mechanism. Blood. 2011;117(20):5372–5380. [PubMed]
63. Fuld S. Borland G. Yarwood SJ. Elevation of cyclic AMP in Jurkat T-cells provokes distinct transcriptional responses through the protein kinase A (PKA) and exchange protein activated by cyclic AMP (EPAC) pathways. Exp Cell Res. 2005;309(1):161–173. [PubMed]
Articles from AIDS Research and Human Retroviruses are provided here courtesy of
Mary Ann Liebert, Inc.